Published in Intern Med on June 16, 2008
Gastric cancer. Lancet (2009) 7.27
Differences in interleukin 8 expression in Helicobacter pylori-infected gastric mucosa tissues from patients in Bhutan and the Dominican Republic. Hum Pathol (2014) 2.07
c-Src and c-Abl kinases control hierarchic phosphorylation and function of the CagA effector protein in Western and East Asian Helicobacter pylori strains. J Clin Invest (2012) 1.53
A comprehensive sequence and disease correlation analyses for the C-terminal region of CagA protein of Helicobacter pylori. PLoS One (2009) 1.34
Characteristics of gastric cancer in Asia. World J Gastroenterol (2014) 1.26
Diverse characteristics of the CagA gene of Helicobacter pylori strains collected from patients from southern vietnam with gastric cancer and peptic ulcer. J Clin Microbiol (2009) 1.25
MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol (2012) 1.21
Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract (2012) 1.12
Prevalence of vacA, cagA and babA2 genes in Cuban Helicobacter pylori isolates. World J Gastroenterol (2009) 1.11
Attenuated CagA oncoprotein in Helicobacter pylori from Amerindians in Peruvian Amazon. J Biol Chem (2011) 1.06
Helicobacter pylori infection and gastroduodenal diseases in Vietnam: a cross-sectional, hospital-based study. BMC Gastroenterol (2010) 1.03
Should we still subcategorize helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil (2011) 1.00
Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol (2014) 0.99
Treatment of resectable gastric cancer. Therap Adv Gastroenterol (2012) 0.99
Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. Dig Dis Sci (2012) 0.99
Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Fam Cancer (2012) 0.98
The cag PAI is intact and functional but HP0521 varies significantly in Helicobacter pylori isolates from Malaysia and Singapore. Eur J Clin Microbiol Infect Dis (2010) 0.96
Cronkhite-Canada syndrome complicated with huge intramucosal gastric cancer. Gastric Cancer (2009) 0.95
Evolutionary History of the Helicobacter pylori Genome: Implications for Gastric Carcinogenesis. Gut Liver (2012) 0.92
Genome sequences of 65 Helicobacter pylori strains isolated from asymptomatic individuals and patients with gastric cancer, peptic ulcer disease, or gastritis. Pathog Dis (2013) 0.91
Gastric cancers of Western European and African patients show different patterns of genomic instability. BMC Med Genomics (2011) 0.88
Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract (2012) 0.86
Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma. Int J Clin Exp Pathol (2014) 0.84
Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol (2015) 0.83
Glutathione S-transferase T1 (GSTT1) gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiologic studies. Dig Dis Sci (2009) 0.83
Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer. Korean J Intern Med (2013) 0.83
Molecular Epidemiology of Helicobacter pylori Infection in Nepal: Specific Ancestor Root. PLoS One (2015) 0.82
Elevated Preoperative Serum Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) Ratio Is Associated with Better Prognosis in Patients Undergoing Curative Treatment for Gastric Adenocarcinoma. Int J Mol Sci (2016) 0.81
Mixed infection with cagA positive and cagA negative strains of Helicobacter pylori lowers disease burden in The Gambia. PLoS One (2011) 0.80
Vaccinating against Helicobacter pylori in the developing world. Gut Microbes (2013) 0.80
A Lymph Node Staging System for Gastric Cancer: A Hybrid Type Based on Topographic and Numeric Systems. PLoS One (2016) 0.79
Helicobacter pylori infection predicts favorable outcome in patients with gastric cancer. Curr Oncol (2013) 0.79
Trends and results in treatment of gastric cancer over last two decades at single East European centre: a cohort study. BMC Surg (2014) 0.79
The Prevalence of Helicobacter pylori Virulence Factors in Bhutan, Vietnam, and Myanmar Is Related to Gastric Cancer Incidence. Biomed Res Int (2015) 0.79
Prognostic relevance of gastric cancer staging by endoscopic ultrasound. Surg Endosc (2012) 0.78
In silico evolutionary analysis of Helicobacter pylori outer membrane phospholipase A (OMPLA). BMC Microbiol (2012) 0.77
Helicobacter pylori virulence genes in the five largest islands of Indonesia. Gut Pathog (2015) 0.77
Diversity of Helicobacter pylori genotypes in Iranian patients with different gastroduodenal disorders. World J Gastroenterol (2013) 0.77
Relationship between vacA Types and Development of Gastroduodenal Diseases. Toxins (Basel) (2016) 0.77
EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new? Curr Drug Targets (2010) 0.76
Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease. Pediatr Res (2016) 0.75
The clearance effect of bovine anti-Helicobacter pylori antibody-containing milk in O blood group Helicobacter pylori-infected patients: a randomized double-blind clinical trial. J Transl Med (2015) 0.75
Helicobacter pylori strains harboring babA2 from Indian sub population are associated with increased virulence in ex vivo study. Gut Pathog (2016) 0.75
Survival of non-Western first generations immigrants with stomach cancer in North East Netherlands. Br J Cancer (2011) 0.75
Helicobacter pylori from gastric cancer and duodenal ulcer show same phylogeographic origin in the Andean region in Colombia. PLoS One (2014) 0.75
Isolation and characterization of Helicobacter pylori recovered from gastric biopsies under anaerobic conditions. Diagn Microbiol Infect Dis (2016) 0.75
Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy. Gastroenterol Res Pract (2017) 0.75
Effect of treatment failure on the CagA EPIYA motif in Helicobacter pylori strains from Colombian subjects. World J Gastroenterol (2017) 0.75
Apparent diffusion coefficient by diffusion-weighted magnetic resonance imaging as a sole biomarker for staging and prognosis of gastric cancer. Chin J Cancer Res (2017) 0.75
cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A (1996) 16.69
Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem (1995) 12.61
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A (1993) 11.85
Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res (1995) 11.07
Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science (2000) 7.99
Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production. Infect Immun (1993) 7.75
Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev (2006) 7.72
Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol (2004) 7.22
Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science (1998) 6.99
An African origin for the intimate association between humans and Helicobacter pylori. Nature (2007) 6.91
Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem (1992) 6.54
Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci U S A (1999) 6.34
Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst (1995) 6.07
Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science (1995) 5.73
Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology (1997) 5.24
Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci U S A (2000) 5.07
Recombination and clonal groupings within Helicobacter pylori from different geographical regions. Mol Microbiol (1999) 4.72
Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut (1997) 4.70
Who ate whom? Adaptive Helicobacter genomic changes that accompanied a host jump from early humans to large felines. PLoS Genet (2006) 4.65
Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci U S A (1999) 4.55
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med (2000) 3.74
A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A (2000) 3.66
A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology (2007) 3.54
Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci U S A (2002) 3.50
Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology (1999) 3.37
Variants of the 3' region of the cagA gene in Helicobacter pylori isolates from patients with different H. pylori-associated diseases. J Clin Microbiol (1998) 3.31
Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology (2002) 3.27
Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol (2005) 3.25
The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol (2006) 3.07
Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science (2004) 3.06
Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science (2003) 3.00
Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus. Cell Microbiol (2000) 2.91
Distinguishing human ethnic groups by means of sequences from Helicobacter pylori: lessons from Ladakh. Proc Natl Acad Sci U S A (2004) 2.83
Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India. J Bacteriol (2000) 2.81
Expanding allelic diversity of Helicobacter pylori vacA. J Clin Microbiol (1998) 2.73
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat Genet (2003) 2.67
Gain and loss of multiple genes during the evolution of Helicobacter pylori. PLoS Genet (2005) 2.61
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Relationship between the cagA 3' repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH. Gastroenterology (1999) 2.44
Heterogeneity in the Helicobacter pylori vacA and cagA genes: association with gastroduodenal disease in South Africa? Gut (1999) 2.43
Determinants and consequences of different levels of CagA phosphorylation for clinical isolates of Helicobacter pylori. Gastroenterology (2004) 2.40
Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Helicobacter (1998) 2.39
Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J Exp Med (2000) 2.37
Genetic and functional characterization of the alpAB gene locus essential for the adhesion of Helicobacter pylori to human gastric tissue. Mol Microbiol (1999) 2.06
Allelic Variation within Helicobacter pylori babA and babB. Infect Immun (2001) 2.02
Helicobacter pylori HopH (OipA) and bacterial pathogenicity: genetic and functional genomic analysis of hopH gene polymorphisms. J Infect Dis (2006) 2.02
Molecular epidemiology of Helicobacter pylori: separation of H. pylori from East Asian and non-Asian countries. Epidemiol Infect (2000) 1.97
East Asian genotypes of Helicobacter pylori strains in Amerindians provide evidence for its ancient human carriage. Proc Natl Acad Sci U S A (2002) 1.92
The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J Exp Med (2003) 1.87
Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology (2004) 1.79
Influence of EPIYA-repeat polymorphism on the phosphorylation-dependent biological activity of Helicobacter pylori CagA. Gastroenterology (2006) 1.77
Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion. Proc Natl Acad Sci U S A (2004) 1.77
Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut (2005) 1.62
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Production of a cytotoxin by Helicobacter pylori. Rev Infect Dis (1991) 1.59
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Determinants of non-toxicity in the gastric pathogen Helicobacter pylori. J Biol Chem (2003) 1.51
Correlation between variation of the 3' region of the cagA gene in Helicobacter pylori and disease outcome in Japan. J Infect Dis (2002) 1.46
The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer (2000) 1.46
Regulation of interleukin-6 promoter activation in gastric epithelial cells infected with Helicobacter pylori. Mol Biol Cell (2005) 1.37
Polymorphisms of Helicobacter pylori HP0638 reflect geographic origin and correlate with cagA status. J Clin Microbiol (2002) 1.35
Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter (2004) 1.35
Natural diversity in the N terminus of the mature vacuolating cytotoxin of Helicobacter pylori determines cytotoxin activity. J Bacteriol (2000) 1.32
Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Cancer (1999) 1.31
Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. Infect Immun (2004) 1.30
Helicobacter pylori CagA seropositivity and gastric carcinoma risk in a Japanese American population. J Infect Dis (2002) 1.14
Regulation of RANTES promoter activation in gastric epithelial cells infected with Helicobacter pylori. Infect Immun (2005) 1.12
Distinct diversity of the cag pathogenicity island among Helicobacter pylori strains in Japan. J Clin Microbiol (2004) 1.12
Functional and intracellular signaling differences associated with the Helicobacter pylori AlpAB adhesin from Western and East Asian strains. J Biol Chem (2007) 1.06
Helicobacter pylori vacuolating cytotoxin, VacA, is responsible for gastric ulceration. J Biochem (2004) 0.98
Regulation of IL-18 in Helicobacter pylori infection. J Immunol (2008) 0.93
The functional status of the Helicobacter pylori sabB adhesin gene as a putative marker for disease outcome. Helicobacter (2004) 0.91
Functional variability of cagA gene in Japanese isolates of Helicobacter pylori. Gene (2004) 0.80
Clarifications regarding the 3' repeat region of the cagA gene in Helicobacter pylori and clinical outcome. J Clin Microbiol (2001) 0.80
SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science (2001) 5.49
Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol (2005) 3.51
Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci U S A (2002) 3.50
Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter (2010) 2.50
Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc (2013) 2.30
An irradiation-free nonmyeloablative bone marrow transplantation model: importance of the balance between donor T-cell number and the intensity of conditioning. Transplantation (2005) 2.08
Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun (2003) 2.01
Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol (2010) 1.98
Relationship between histopathologic gastritis and mucosal microvascularity: observations with magnifying endoscopy. Gastrointest Endosc (2003) 1.96
Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology (2003) 1.87
Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology (2003) 1.85
Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology (2008) 1.83
Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter (2006) 1.67
Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue, including changes after treatment. Gastrointest Endosc (2008) 1.67
Long-term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gastrointest Endosc (2002) 1.65
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol (2003) 1.57
Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology (2002) 1.54
Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann Hematol (2005) 1.48
Rapid degradation of Cdt1 upon UV-induced DNA damage is mediated by SCFSkp2 complex. J Biol Chem (2004) 1.46
Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol (2007) 1.45
Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol (2003) 1.45
ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses. Nat Immunol (2010) 1.43
Primary paraganglioma of the head of pancreas: contribution of combinatorial image analyses to the diagnosis of disease. Intern Med (2005) 1.40
Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol (2004) 1.37
Endoscopic diagnosis of early squamous neoplasia of the esophagus with iodine staining: high-grade intra-epithelial neoplasia turns pink within a few minutes. J Gastroenterol Hepatol (2007) 1.33
Endoscopic submucosal dissection for treatment of early stage hypopharyngeal carcinoma. Gastrointest Endosc (2006) 1.28
Effects of Helicobacter pylori CagA protein on the growth and survival of B lymphocytes, the origin of MALT lymphoma. Oncogene (2003) 1.25
Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res (2007) 1.23
Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation (2005) 1.22
The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica (2008) 1.21
Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol (2009) 1.19
The ability of a novel blue laser imaging system for the diagnosis of invasion depth of colorectal neoplasms. J Gastroenterol (2013) 1.18
High salt diets dose-dependently promote gastric chemical carcinogenesis in Helicobacter pylori-infected Mongolian gerbils associated with a shift in mucin production from glandular to surface mucous cells. Int J Cancer (2006) 1.18
Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf (2005) 1.17
Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun (2005) 1.13
The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol (2009) 1.13
Clinicopathological analysis of early-stage gastric cancers detected after successful eradication of Helicobacter pylori. Helicobacter (2011) 1.12
Spontaneous resolution of cap polyposis: case report. Gastrointest Endosc (2003) 1.12
RNF43 interacts with NEDL1 and regulates p53-mediated transcription. Biochem Biophys Res Commun (2010) 1.11
Real-time monitoring of a digestive tract marker to reduce adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal tumors. Int J Radiat Oncol Biol Phys (2005) 1.10
Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutr (2009) 1.10
Monitoring of plasma imatinib concentration for the effective treatment of CML patients. Leuk Res (2004) 1.09
Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene (2003) 1.08
IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater's ampulla and the bile duct. J Gastroenterol Hepatol (2010) 1.08
What is an adequate management strategy for pharyngeal low-grade dysplasia? Gastrointest Endosc (2013) 1.08
Strategy for eliminating gastric cancer in Japan. Helicobacter (2010) 1.08
Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol (2015) 1.08
Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis. J Clin Oncol (2005) 1.06
Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging (2002) 1.06
Autoimmune pancreatitis associated with hemorrhagic pseudocysts: a case report and literature review. Intern Med (2008) 1.06
TRIM29 negatively regulates p53 via inhibition of Tip60. Biochim Biophys Acta (2011) 1.06
A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells. Clin Cancer Res (2010) 1.04
Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol (2013) 1.03
Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med (2010) 1.03
Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter (2004) 1.02
A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study. J Gastroenterol (2014) 1.01
Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma (2004) 1.00
Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol (2008) 1.00
Allogeneic bone marrow transplantation from an unrelated donor for the treatment of chronic myelogenous leukemia in blast crisis in a patient with Kleinfelter's syndrome. Leuk Lymphoma (2004) 1.00
Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol (2013) 1.00
The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. Exp Mol Pathol (2010) 0.99
Recent development of gastric cancer prevention. Jpn J Clin Oncol (2012) 0.99
Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells. Cancer Sci (2014) 0.99
Novel Parachlamydia acanthamoebae quantification method based on coculture with amoebae. Appl Environ Microbiol (2008) 0.98
Rikkunshito ameliorates the aging-associated decrease in ghrelin receptor reactivity via phosphodiesterase III inhibition. Endocrinology (2009) 0.98
Three cases of retroperitoneal schwannoma diagnosed by EUS-FNA. World J Gastroenterol (2011) 0.98
Delayed reduction in left ventricular function following treatment of non-Hodgkin's lymphoma with chemotherapy and rituximab, unrelated to acute infusion reaction. Cardiology (2006) 0.97
Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter (2014) 0.96
A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol (2013) 0.95
Decreased plasma ghrelin contributes to anorexia following novelty stress. Am J Physiol Endocrinol Metab (2011) 0.95
Endoscopic submucosal dissection (ESD) is being accepted as a new procedure of endoscopic treatment of early gastric cancer. Intern Med (2005) 0.95
Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system. Mol Immunol (2007) 0.95
Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol (2007) 0.95
Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol (2004) 0.94
Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res (2007) 0.94
EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma. Gastrointest Endosc (2004) 0.94
Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol (2011) 0.94
Evaluation of the effects of strain-specific antigen variation on the accuracy of serologic diagnosis of Helicobacter pylori infection. J Clin Microbiol (2003) 0.94
p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. Int J Cancer (2010) 0.94
Impaired ghrelin signaling is associated with gastrointestinal dysmotility in rats with gastroesophageal reflux disease. Am J Physiol Gastrointest Liver Physiol (2012) 0.93
Fascin is involved in tumor necrosis factor-alpha-dependent production of MMP9 in cholangiocarcinoma. Lab Invest (2009) 0.93
MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10. Blood (2005) 0.93
Preoperative biliary drainage for hilar cholangiocarcinoma: which stent should be selected? J Hepatobiliary Pancreat Sci (2011) 0.93